Home › Trials › NCT04935853

Identifying markers to predict treatment response in bile duct cancer

Marqueurs Pronostiques et prédictifs de réponse Aux Traitements Chez Les Patients Atteints de Cancer Des Voies Biliaires : Cohorte Multicentrique ACABi PRONOBIL

Observational GERCOR - Multidisciplinary Oncology Cooperative Group · NCT04935853

This study is trying to find markers that can help doctors predict how well different treatments will work for people with bile duct cancer.

Quick facts

Study typeObservational
Enrollment1350 (estimated)
Ages18 Years and up
SexAll
SponsorGERCOR - Multidisciplinary Oncology Cooperative Group Academic / other
Drugs / interventionschemotherapy
Locations32 sites (Amiens and 31 other locations)
Trial IDNCT04935853 on ClinicalTrials.gov

What this trial studies

This study aims to identify prognostic and predictive markers that can help determine how patients with bile duct cancer respond to various treatments, including surgery, chemotherapy, and targeted therapies. It is a multi-center, cohort study that will collect data from patients diagnosed between 2003 and 2030, with a follow-up period of 10 years from the initial diagnosis. The study will evaluate the effectiveness and tolerance of current treatment practices and will include both retrospective and prospective data collection methods.

Who should consider this trial

Good fit: Ideal candidates for this study are adults over 18 years old diagnosed with any form of bile duct cancer between 2003 and 2030.

Not a fit: Patients who are under guardianship, pregnant, breastfeeding, or unable to comply with the study protocol may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could lead to more personalized treatment strategies for patients with bile duct cancer, improving their outcomes.

How similar studies have performed: Other studies have shown promise in identifying predictive markers for cancer treatment responses, making this approach both relevant and potentially impactful.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* All locations of primitives (intrahepatic CCA, extrahepatic CCA, adenocarcinoma of the gallbladder; ampullomas excluded)
* Age \> 18 years
* Diagnosed between 2003 and 2030 (minimum follow-up 2 years)
* Written written non-opposition +/- signed informed consent for genetic studies (N.B.:

exemption requested for a deceased patient) N.B. Authorized inclusion in a therapeutic research protocol

Exclusion Criteria:

* Patient under guardianship, curatorship or legal protection
* Pregnant or breastfeeding women
* Any medical, psychological or social situation, which could prevent the compliance with the protocol according to the investigator's assessment
* Refusal to participate in the study

Where this trial is running

Amiens and 31 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Biliary Tract Cancerpredictiveprognosticbiliary track cancer
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.